Compare Dyne Therapeutics Inc. Common Stock (DYN) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs S&P Global Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while S&P Global Inc trades at $408.03 (market cap $120.87B). The key difference: S&P Global Inc is far larger — about 42.3× Dyne Therapeutics Inc. Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and S&P Global Inc for 124 Days on average.
| DYN | SPGI | |
|---|---|---|
Market Cap | $2.86B | $120.87B |
Volume | 3,341,579 | 1,391,754 |
Sector | Health | Financials |
52-Week High | $26.78 | $517.92 |
52-Week Low | $14.60 | $370.42 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $2.18B | $132.35B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
S&P Global (SPGI) trades at $408.57, down 0.88% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong fundamentals with Q1 and Q2 2026 earnings beats, revenue growth to $15.34B in 2025, and robust profitability margins. Recent news highlights expansion into digital asset risk assessment and AI-driven growth initiatives.
Outlook remains positive with an 85.7% analyst buy rating and a $509.50 consensus price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic sensitivity, but the firm's entrenched market position and cash flow stability support a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
